Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases

Expert Opinion on Biological Therapy

Volumn 7, Issue 5, 2007, Pages 691-704

  Angyal, Adrienn ^a   Prechl, József ^a   Sármay, Gabriella ^a  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Antibody therapy; Autoimmunity; Inflammation; Single chain fragment variable

Indexed keywords

ABATACEPT; AUTOANTIBODY; BELIMUMAB; CD137 ANTIGEN; CD20 ANTIBODY; CD40 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ECULIZUMAB; EPRATUZUMAB; ETANERCEPT; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY CD28; PEXELIZUMAB; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC ENCEPHALITIS; ANTIGEN ANTIBODY COMPLEX; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; GENE THERAPY; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOGENICITY; IMMUNOPATHOLOGY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NEPHRITIS; NONHODGKIN LYMPHOMA; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

EID: 34248222152     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.5.691     Document Type: Review

References (128)

1. LESAGE S, GOODNOW CC: Organ-specific autoimmune disease: a deficiency of tolerogenic stimulation. J. Exp. Med. (2001) 194(5):F31-F36.
2. ENZLER T, BONIZZI G, SILVERMAN GJ et al.: Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 25(3):403-415.
3. YOUINOU P, HILLION S, JAMIN C et al.: B lymphocytes on the front line of autoimmunity. Autoimmun. Rev. (2006) 5(3):215-221. •• This review summarises the newly emerging facts on the importance of B cells in autoimmune diseases.
4. DORNER T: Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J. Rheumatol. Suppl. (2006) 77:3-11.
5. JOZSI M, PRECHL J, BAJTAY Z, ERDEI A: Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J. Immunol. (2002) 168(6):2782-2788.
6. RABINOVITCH N, GELFAND EW: Expression of functional activating and inhibitory Fcgamma receptors on human B cells. Int. Arch. Allergy Immunol. (2004) 133(3):285-294.
7. BARRINGTON RA, ZHANG M, ZHONG X et al.: CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J. Immunol. (2005) 175(5):2859-2867.
8. BOSSEN C, SCHNEIDER P: BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. (2006) 18(5):263-275. •• Comprehensive review of the new members of the TNF family, BAFF and April, and their receptors regulating B cell development.
9. TAYLOR PC, WILLIAMS RO, MAINI RN: Immunotherapy for rheumatoid arthritis. Curr. Opin. Immunol. (2001) 13(5):611-616.
10. KAPLAN M: Eculizumab (Alexion). Curr. Opin. Investig. Drugs (2002) 3(7):1017-1023.
11. TAYLOR PC: Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol. Biotechnol. (2001) 19(2):153-168.
12. FLEISCHMANN RM, SCHECHTMAN J, BENNETT R et al.: Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. (2003) 48(4):927-934.
13. HASLER P: Biological therapies directed against cells in autoimmune disease. Springer Semin. Immunopathol. (2006) 27(4):443-456.
14. FELDMANN M, STEINMAN L: Design of effective immunotherapy for human autoimmunity. Nature (2005) 435(7042):612-619. • Comparative study on antigen-specific and -nonspecific therapies applied in autoimmune diseases.
15. CLARK M: Antibody humanization: a case of the 'Emperor's new clothes'? Immunol. Today (2000) 21(8):397-402.
16. BOULIANNE GL, HOZUMI N, SHULMAN MJ: Production of functional chimaeric mouse/human antibody. Nature (1984) 312(5995):643-646.
17. MORRISON SL, JOHNSON MJ, HERZENBERG LA, OI VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA (1984) 81(21):6851-6855.
18. KUUS-REICHEL K, GRAUER LS, KARAVODIN LM et al.: Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. (1994) 1(4):365-372.
19. WINTER G, GRIFFITHS AD, HAWKINS RE, HOOGENBOOM HR: Making antibodies by phage display technology. Annu. Rev. Immunol. (1994) 12:433-455.
20. LOW NM, HOLLIGER PH, WINTER G: Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. (1996) 260(3):359-368.
21. BRUGGEMANN M, SPICER C, BULUWELA L et al.: Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus. Eur. J. Immunol. (1991) 21(5):1323-1326.
22. MENDEZ MJ, GREEN LL, CORVALAN JR et al.: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. (1997) 15(2):146-156.
23. BENJAMIN RJ, COBBOLD SP, CLARK MR, WALDMANN H: Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. (1986) 163(6):1539-1552.
24. SUNTHARALINGAM G, PERRY MR, WARD S et al.: Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. (2006) 355(10):1018-1028.
25. KLEINSCHMIDT-DEMASTERS BK, TYLER KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-la for multiple sclerosis. N Engl. J. Med. (2005) 353(4):369-374.
26. LANGER-GOULD A, ATLAS SW, GREEN AJ, BOLLEN AW, PELLETIER D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. (2005) 353(4):375-381.
27. VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. (2005) 353(4):362-368.
28. WEAVER AL: Efficacy and safety of the anti-TNF biologic agents. Mod. Rheumatol. (2004) 14(2):101-112.
29. FELDMANN M, MAINI RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. (2001) 19:163-196. •• This comprehensive review summarises the experience obtained with anti-TNF-α and TNF-α inhibitors in the clinic.
30. BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41(12):2196-2204.
31. CAMPION GV, LEBSACK ME, LOOKABAUGH J, GORDON G, CATALANO M: Dose-tange and dose-frequency study of tecombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. (1996) 39(7):1092-1101.
32. PRESTA LG: Engineering antibodies for therapy. Curr. Pharm. Biotechnol. (2002) 3(3):237-256.
33. FREDERICKS ZL, FORTE C, CAPUANO IV et al.: Identification of potent human anti-IL-1RI antagonist antibodies. Protein Eng. Des. Sel. (2004) 17(1):95-106.
34. COSTA GL, SANDORA MR, NAKAJIMA A et al.: Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J. Immunol. (2001) 167(4):2379-2387.
35. NAKAJIMA A, SEROOGY CM, SANDORA MR et al.: Antigen-specific T cell-mediated gene therapy in collagen-induced arthtitis. J. Clin. Invest. (2001) 107(10):1293-1301.
36. FIFE BT, GRIFFIN MD, ABBAS AK, LOCKSLEY RM, BLUESTONE JA: Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Invest. (2006) 116(8):2252-2261.
37. NAKAJIMA A: Application of cellular gene therapy for rheumatoid arthritis. Mod. Rheumatol. (2006) 16(5):269-275.
38. DALL'ERA M, DAVIS J: CTLA4Ig: a novel inhibitor of costimulation. Lupus (2004) 13(5):372-376.
39. EHLERS M, FUKUYAMA H, MCGAHATL, ADEREM A, RAVETCH JV: TLR9/MyD88 signaling is required for class switching ro pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. (2006) 203(3):553-561.
40. CHRISTENSEN SR, SHUPE J, NICKERSON K et al.: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 25(3):417-428.
41. GRAMMER AC, LIPSKY PE: B cell abnormalities in systemic lupus erythematosus. Arthritis Res. Ther. (2003) 5(Suppl. 4):S22-S27. • This article describes the possible defect of B cell interactions in systemic autoimmune disorders.
42. DING C, JONES G: Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr. Opin. Investig. Drugs (2006) 7(5):464-472.
43. COHEN SB: Updates from B cell trials: efficacy. J. Rheumatol. Suppl. (2006) 77:12-17.
44. ERNST JA, LI H, KIM HS et al.: Isolation and characterization of the B-cell marker CD20. Biochemistry (2005) 44(46):15150-15158.
45. CAMBRIDGE G, LEANDRO MJ, EDWARDS JC et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. (2003) 48(8):2146-2154.
46. STOHL W, LOONEY RJ: B cell depletion therapy in systemic theumatic diseases: different strokes for different folks? Clin. Immunol. (2006) 121(1):1-12.
47. COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. (2006) 54(9):2793-2806.
48. ALOISI F, PUJOL-BORRELL R: Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. (2006) 6(3):205-217.
49. MARTIN F, CHAN AC: Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity (2004) 20(5):517-527.
50. EDWARDS JC, CAMBRIDGE G, LEANDRO MJ: B cell depletion therapy in rheumaric disease. Best Pract. Res. Clin. Rheumatol. (2006) 20(5):915-928.
51. DORNER T, KAUFMANN J, WEGENER WA et al.: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of sysremic lupus erythematosus. Arthritis Res. Ther. (2006) 8(3):R74.
52. CARNAHAN J, WANG P, KENDALL R et al.: Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res. (2003) 9(10 Pt 2):3982S-3990S.
53. NIMMERJAHN F, RAVETCH JV: Fcgamma receptors: old friends and new family members. Immunity (2006) 24(1):19-28.
54. SOLOMON S, KASSAHN D, ILLGES H: The role of the complement and the Fc gamma R system in the pathogenesis of arthritis. Arthritis Res. Ther. (2005) 7(4):129-135. •• Review on the role of C5a in the transcriptional regulation of Fcγ receptors and, thus, in the complex regulation of autoimmune disease.
55. STEWART-AKERS AM, CUNNINGHAM A, WASKO MC, MOREL PA: Fc gamma R expression on NK cells influences disease severity in rheumatoid arthritis. Genes Immun. (2004) 5(7):521-529.
56. NIGROVIC PA, LEE DM: Mast cells in inflammatory arthritis. Arthritis Res. Ther. (2005) 7(1):1-11.
57. GERARD C, GERARD NP: C5A anaphylatoxin and its seven transmembrane- segment receptor. Annu. Rev. Immunol. (1994) 12:775-808.
58. ISAAK A, PRECHL J, GERGELY J, ERDEI A: The role of CR2 in autoimmunity. Autoimmunity (2006) 39(5):357-366.
59. DREJA H, ANNENKOV A, CHERNAJOVSKY Y: Soluble complement receptor 1(CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis Rheum. (2000) 43(8):1698-1709.
60. WHISS PA: Pexelizumab Alexion. Curr. Opin. Investig. Drugs (2002) 3(6):870-877.
61. KORGANOW AS, JI H, MANGIALAIO S et al.: From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity (1999) 10(4):451-461.
62. KYBURZ D, CORR M: The KRN mouse model of inflammatory arthritis. Springer Semin. Immunopathol. (2003) 25(1):79-90.
63. TAKAI T: Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. (2002) 2(8):580-592. •• Comprehensive review on the role of activating and inhibitory Fcγ receptors in the onset and maintenance of autoimmune diseases.
64. TAKAI T: Fc receptors and their role in immune regulation and autoimmunity. J. Clin. Immunol. (2005) 25(1):1-18.
65. TSUCHIYA N, KYOGOKU C: Role of Fc gamma recepror IIb polymorphism in the genetic background of systemic lupus erythematosus: insights from Asia. Autoimmunity (2005) 38(5):347-352.
66. SIRIBOONRIT U, TSUCHIYA N, SIRIKONG M et al.: Association of Fcgamma receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. Tissue Antigens (2003) 61(5):374-383.
67. KONO H, KYOGOKU C, SUZUKI T et al.: FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. (2005) 14(19):2881-2892.
68. MACKAY M, STANEVSKY A, WANG T et al.: Selective dysregularion of the FcgammaIIB recepror on memory B cells in SLE. J. Exp. Med. (2006) 203(9):2157-2164.
69. GAULD SB, MERRELL KT, CAMBIER JC: Silencing of autoreactive B cells by anergy: a fresh perspective. Curr. Opin. Immunol. (2006) 18(3):292-297.
70. RANKIN CT, VERI MC, GORLATOV S et al.: CD32B, the human inhibitory Fc-gamma recepror IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood (2006) 108(7):2384-2391.
71. SULICA A, MOREL P, METES D, HERBERMAN RB: Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int. Rev. Immunol. (2001) 20(3-4):371-414.
72. BORUCHOV AM, HELLER G, VERI MC et al.: Activating and inhibitory IgG Fc receprors on human DCs mediate opposing functions. J. Clin. Invest. (2005) 115(10):2914-2923.
73. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256(5517):495-497.
74. BIRD RE, HARDMAN KD, JACOBSON JW et al.: Single-chain antigen-binding proteins. Science (1988) 242(4877):423-426.
75. KIM SJ, PARK Y, HONG HJ: Antibody engineering for the development of therapeutic antibodies. Mol. Cells (2005) 20(1):17-29. • This review depicts the structural and functional characteristics of antibodies and antibody engineering for the generation and optimisation of therapeutic antibodies.
76. CHAPMAN AP: PEGylated antibodies and antibody fragmenrs for improved therapy: a review. Adv. Drug Deliv. Rev. (2002) 54(4):531-545. •• This review describes previously reported experience with PEGylated antibodies and antibody fragments, and where these types of molecules may find clinical usefulness in the future.
77. CHOWDHURY PS, PASTAN I: Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. (1999) 17(6):568-572.
78. LIPOVSEK D, PLUCKTHUN A: In vitro protein evolution by ribosome display and mRNA display. J. Immunol. Methods (2004) 290(1-2):51- 67. • Methodology for in vitro evolution and selection processes for antibodies, enzymes and even scaffolding proteins.
79. JERMUTUS L, HONEGGER A, SCHWESINGER F, HANES J, PLUCKTHUN A: Tailoring in vitro evolution for protein affinity or stability. Proc. Natl. Acad. Sci. USA (2001) 98(1):75-80.
80. CHAPMAN AP, ANTONIW P, SPITALI M et al.: Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. (1999) 17(8):780-783.
81. CHOWDHURY PS: Engineering hot spots for affinity enhancement of antibodies. Methods Mol. Biol. (2003) 207:179-196.
82. GEORGIOU G, STATHOPOULOS C, DAUGHERTY PS et al.: Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat. Biotechnol. (1997) 15(1):29-34.
83. FRANCISCO JA, CAMPBELL R, IVERSON BL, GEORGIOU G: Production and fluorescence-activated cell sorting oi Escherichia coli expressing a functional antibody fragment on the external surface. Proc. Natl. Acad. Sci. USA (1993) 90(22):10444-10448.
84. HANES J, PLUCKTHUN A: In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA (1997) 94(10):4937-4942.
85. CORBEL SY, ROSSI FM: Latest developments and in vivo use of the Tet system: ex vivo and in vivo delivery of tetracycline-regulated genes. Curr. Opin. Biotechnol. (2002) 13(5):448-452.
86. VAN DER KRAAN PM, VAN DE LOO FA, VAN DEN BERG WB: Role of gene therapy in tissue engineering procedures in rheumatology: the use of animal models. Biomaterials (2004) 25(9):1497-1504. •• Review on gene delivery, targeting of cells and regulation of the transgenes, based on experimental animal models.
87. VAN DE LOO FA, SMEETS RL, VAN DEN BERG WB: Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients? Arthritis Res. Ther. (2004) 6(5):183-196.
88. SMITH R, TARNER IH, HOLLENHORST M et al.: Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis. Gene Ther. (2003) 10(15):1248-1257.
89. TARNER IH, NAKAJIMA A, SEROOGY CM et al.: Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin. Immunol. (2002) 105(3):304-314.
90. TARNER IH, SLAVIN AJ, MCBRIDE J et al.: Treatment of autoimmune disease by adoptive cellular gene therapy. Ann. NY Acad. Sci. (2003) 998:512-519. •• Provides a summary of cell-based treatments of autoimmune diseases, including cells transfected with scFv against TNF-α.
91. TARNER IH, FATHMAN CG: The potential for gene therapy in the treatment of autoimmune disease. Clin. Immunol. (2002) 104(3):204-216.
92. REYNOLDS P, DMITRIEV I, CURIEL D: Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther. (1999) 6(7):1336-1339.
93. BAKKER AC, VAN DE LOO FA, JOOSTEN LA et al.: A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Ther. (2001) 8(23):1785-1793.
94. MOORE PA, BELVEDERE O, ORR A et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 285(5425):260-263.
95. SCHNEIDER P, MACKAY F, STEINER V et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. (1999) 189(11):1747-1756.
96. YAN M, MARSTERS SA, GREWAL IS et al.: Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat. Immunol. (2000) 1(1):37-41.
97. ZHANG J, ROSCHKE V, BAKER KP et al.: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. (2001) 166(1):6-10.
98. ROLINK AG, MELCHERS F: BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr. Opin. Immunol. (2002) 14(2):266-275. •• This review summarises BAFF-mediated effects on B cells: following BAFF-influenced differentiation, immature B cells change their surface-IgM signal transduction machinery and proliferate rather than undergoing apoptosis.
99. ROLINK AG, TSCHOPP J, SCHNEIDER P, MELCHERS F: BAFF is a survival and maturation factor for mouse B cells. Eur. J. Immunol (2002) 32(7):2004-2010.
100. MELCHERS F: Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann. Rheum. Dis. (2003) 62(Suppl. 2):ii25-ii27.
101. WANG H, MARSTERS SA, BAKER T et al.: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol. (2001) 2(7):632-637.
102. KAYAGAKI N, YAN M, SESHASAYEE D et al.: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 17(4):515-524.
103. BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 48(11):3253-3265.
104. CAO P, XIA Z, SONG W, ZHANG S: Neutralizing human anti-B-cell-activating factor of the TNF family (BAFF) scFv selected from phage antibody library. Immunol. Lett. (2005) 101(1):87-94.
105. LIU MY, HAN W, DING YL et al.: Generation and characterization of C305, a murine neutralizing scFv antibody that can inhibit BLyS binding to its receptor BCMA. Acta Biochim. Biophys. Sin. (Shanghai) (2005) 37(6):415-420.
106. LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. (1996) 14:233-258.
107. SUN Y, LIN X, CHEN HM et al.: Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. (2002) 168(3):1457-1465.
108. SUN Y, CHEN HM, SUBUDHI SK et al.: Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. (2002) 8(12):1405-1413.
109. LEE UH, SON JH, LEE JJ et al.: Humanization of antagonistic anti-human 4-IBB monoclonal antibody using a phage-displayed combinatorial library. J. Immunother. (2004) 27(3):201-210.
110. SYTWU HK, LIN WD, ROFFLER SR et al.: Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J. Autoimmun. (2003) 21(3):247-254.
111. TOUBI E, SHOENFEI.D Y: The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 37(6-7):457-464.
112. HOWARD LM, MILLER SD: Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease. Autoimmunity (2004) 37(5):411-418.
113. HOWARD LM, DAL CANTO MC, MILLER SD: Transient anti-CD 154-mediated immunotherapy of ongoing relapsing experimental autoimmune encephalomyelitis induces long-term inhibition of disease relapses. J. Neuroimmunol. (2002) 129(1-2):58-65.
114. HOWARD LM, MIGA AJ, VANDERLUGT CL et al.: Mechanisms of immunotherapeutic intervention by anti-CD40L (CD 154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. (1999) 103(2):281- 290.
115. ELLMARK P, OTTOSSON C, BORREBAECK CA, MALMBORG HAGER AC, FUREBRING C: Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. Immunology (2002) 106(4):456-463.
116. GEJIMA R, TANAKA K, NAKASHIMA T et al.: Human single-chain Fv (scFv) antibody specific to human IL-6 with the inhibitory activity on IL-6-signaling. Hum. Antibodies (2002) 11(4):121-129.
117. SIMS JE: IL-1 and IL-18 receptors, and their extended family. Curr. Opin. Immunol. (2002) 14(1):117-122.
118. HAMASAKI T, HASHIGUCHI S, ITO Y et al.: Human anti-human IL-18 antibody recognizing the IL-18-binding site 3 with IL-18 signaling blocking activity. J. Biochem. (Tokyo) (2005) 138(4):433-442.
119. GRIFFIN MD, HONG DK, HOLMAN PO et al.: Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J. Immunol. (2000) 164(9):4433-4442.
120. JANAS E, PRIEST R, WILDE JI, WHITE JH, MALHOTRA R: Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. (2005) 139(3):439-446.
121. HOLLIGER P, HUDSON PJ: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. (2005) 23(9):1126-1136.
122. KURUCZ I, TITUS JA, JOST CR, SEGAL DM: Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies. Mol. Immunol. (1995) 32(17-18):1443- 1452.
123. KURUCZ I, HILBERT A, KAPUS A et al.: Bacterially expressed human Fc gamma RIIb is soluble and functionally active after in vitro refolding. Immunol. Lett. (2000) 75(1):33-40.
124. MOGHIMI SM, HUNTER AC, MURRAY JC: Nanomedicine: current status and future prospects. FASEB J. (2005) 19(3):311-330. •• This article highlights rational approaches in design and surface engineering of nanoscale vehicles for site-specific drug delivery and medical imaging.
125. ADRIAANSEN J, VERVOORDELDONK MJ, TAK PP: Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) (2006) 45(6):656-668.
126. CAO P, TANG XM, GUAN ZB, DIAO ZY, ZHANG SQ: Production and characterization of a bacterial single-chain antibody fragment specific to B-cell-activating factor of the TNF family. Protein Expr. Purif. (2005) 43(2):157-164.
127. ANNENKOV A, CHERNAJOVSKY Y: Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta. Gene Ther. (2000) 7(8):714-722.
128. BLANK M, WAISMAN A, MOZES E, KOIKE T, SHOENFELD Y: Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome. Int. Immunol. (1999) 11(12):1917-1926.